NEW YORK – Spatial Genomics said on Wednesday that it has raised $56 million in a Series A financing round.
The firm said it will use the funds to accelerate the commercialization of its spatial single-cell multiomic analysis platform, based on the seqFISH technology, scale up its seqFISH laboratory services, and "aggressively expand" its workforce in R&D, engineering, manufacturing, sales, marketing, customer support, and commercial operations.
Fulgent Genetics led the financing round and was joined by 12 West Capital and other investors.
Based on technology originally developed at the California Institute of Technology, Spatial Genomics has developed an integrated platform of reagents, hardware, and software designed to enable multiplexed and multiomic analyses of single cells and intact tissue microenvironments. According to the company, seqFISH enables researchers to identify novel cell types, map genomic organization and nuclear architecture, and analyze cell trajectories more efficiently than existing technologies.
"We are excited to secure this Series A funding, which will support and accelerate our continued growth as a company, and the ongoing commercialization of our seqFISH technology platform," said Kirsten Frieda, CEO and cofounder of Spatial Genomics, in a statement. "SeqFISH enables a highly multiplexed, quantitative, and multiomic analysis of cells and tissues that we believe will be essential to the next era of biological discovery, the continued evolution of precision medicine, drug and biomarker discovery, and the improvement of clinical diagnostics."
Spatial Genomics is based in Pasadena, California, with an additional office in San Diego.